FDA Clears Global Phase III Trials for Osemitamab
The gastric/gastroesophageal cancer treatment is produced by Transcenta.
Transcenta Holding Limited announced that FDA granted clearance for it to proceed with the global Phase III trial for osemitamab.
The trial will test the treatment in conjunction with nivolumab and chemotherapy, according to a press release. osemitamab is a treatment for gastric or gastroesophageal adenocarcinoma.
In a press release, Transcenta executive vice president of global medicine development and chief medical officer Dr. Caroline Germa said, “We are delighted with the positive outcome of the EOP2 meeting. The interim safety, clinical pharmacology and efficacy data we presented fostered a productive dialogue with the FDA. Securing FDA endorsement on critical program elements represents a pivotal milestone in advancing our Phase III trial in the U.S."
Osemitamab is described as a second-generation humanized CLN18.2 targeting antibody with CLDN18.2 binding affinity. It has demonstrated anti-tumor activities in preclinical tumor models.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
